在南朝鲜进行三星和葛赖尔发射癌症检测试验,计划扩大到日本和新加坡。 Samsung and GRAIL launch cancer-detecting test in South Korea, with expansion to Japan and Singapore planned.

Samsung C&T和三星电子公司与GRAIL合作,在南朝鲜启动了加列里多癌症早期检测测试,并计划扩展到日本和新加坡。 Samsung C&T and Samsung Electronics have partnered with GRAIL to launch the Galleri multi-cancer early detection test in South Korea, with plans to expand to Japan and Singapore. 这笔交易包括投资1.1亿美元,每股70.05美元,有待监管批准,预计2026年初进行。 The deal includes an $110 million investment at $70.05 per share, pending regulatory approval, expected in early 2026. Samsung C&T将作为该地区GRAIL的独家经销商进行商业化,最初在美国进行测试。 Samsung C&T will lead commercialization as GRAIL’s exclusive distributor in the region, with tests initially processed in the U.S. 合作还开辟了对基因组学和数字健康一体化进行联合研究的潜力,支持三星推动先进的保健技术。 The collaboration also opens potential for joint research in genomics and digital health integration, supporting Samsung’s push into advanced healthcare technologies.